Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 3/20 | 0.32 |
| ▸ | ALPI | P09923 | 3/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590096 | 0.84 | GAA (0.37) | ATRCYP4F2CYP4A11GAA | |
| SCHEMBL25210691 | 0.80 | GAA (0.32) | ATRCYP4F2CYP4A11GAA | |
| SCHEMBL2593255 | 0.79 | CNR1 (0.35) | ATRCYP4F2CYP4A11 | |
| SCHEMBL18448466 | 0.76 | CYP4F2 (0.41) | ATRCYP4F2CYP4A11 | |
| SCHEMBL14726472 | 0.76 | CYP4F2 (0.42) | ATRCYP4F2CYP4A11GAA | |
| SCHEMBL18758369 | 0.73 | CYP4F2 (0.37) | ATRCYP4F2CYP4A11GAA | |
| SCHEMBL22604901 | 0.73 | GAA (0.42) | ATRCYP4F2CYP4A11GAA | |
| SCHEMBL8932232 | 0.73 | CYP4F2 (0.44) | ATRCYP4F2CYP4A11GAA | |
| SCHEMBL22824028 | 0.72 | MEN1 (0.37) | ATRCYP4F2CYP4A11GAA | |
| SCHEMBL9939733 | 0.72 | ALDH1A1 (0.40) | ATRCYP4F2CYP4A11GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| EP-4188549-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-2563358-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | Merck Sharp & Dohme Corp. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011137219-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | SCHERING CORPORATION (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | ATR 689/4885ALPL 3148/4885ALPI 3066/4885 |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | ATR 3239/4885ALPL 1426/4885ALPI 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.